Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Medtronic (NYSE:MDT) is currently navigating a landscape marked by both promising innovations and significant challenges.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Medtronic (MDT – Research Report), with a ...

Medtronic delivered a strong first-quarter ... in 2023. This helped the Diabetes segment's organic sales increase by 12.6%. This recovery is particularly important. Weakness in the Diabetes ...

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic reported adjusted earnings per share of $1.23 for ... Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. In the fiscal first quarter, Cardiovascular revenues increased 6.9% ...

Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...

Medtronic's business is diversified. The company boasts dozens of devices across four main segments: Medical surgical, neuroscience, cardiovascular, and diabetes. Though Medtronic records ...

The company operates in four business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Medtronic sells products in many end markets in these segments. It is usually the ...

Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like ...

Medtronic is also at an interesting inflection ... where there's a big patient need and a lot of patients, areas like diabetes or AFib, and we're counting on hypertension. But from an industry ...